A detailed history of Y Intercept (Hong Kong) LTD transactions in Bio N Tech Se stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 6,046 shares of BNTX stock, worth $730,840. This represents 0.05% of its overall portfolio holdings.

Number of Shares
6,046
Holding current value
$730,840
% of portfolio
0.05%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$78.36 - $124.66 $473,764 - $753,694
6,046 New
6,046 $718,000
Q4 2023

Feb 13, 2024

BUY
$90.91 - $112.75 $1.06 Million - $1.32 Million
11,696 New
11,696 $1.23 Million
Q4 2022

Feb 14, 2023

SELL
$118.43 - $186.05 $474,904 - $746,060
-4,010 Closed
0 $0
Q3 2022

Feb 14, 2023

SELL
$127.65 - $183.11 $3.42 Million - $4.91 Million
-26,790 Reduced 86.98%
4,010 $540,000
Q2 2022

Aug 08, 2022

BUY
$123.25 - $186.24 $3.8 Million - $5.74 Million
30,800 New
30,800 $4.59 Million
Q1 2022

May 16, 2022

SELL
$126.25 - $231.85 $126,628 - $232,545
-1,003 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$216.64 - $362.52 $1.14 Million - $1.91 Million
-5,258 Reduced 83.98%
1,003 $259,000
Q3 2021

Nov 15, 2021

BUY
$205.93 - $447.23 $1.29 Million - $2.8 Million
6,261 New
6,261 $1.71 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $29.3B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.